Celonic GroupThe Celonic Group and CARBOGEN AMCIS AG have formed a strategic alliance to offer a fully integrated Antibody Drug Conjugate (ADC) development and manufacturing platform. This partnership combines Celonic’s biologics expertise with CARBOGEN AMCIS’s payload synthesis and conjugation capabilities, creating a seamless, end-to-end solution for ADC developers.
Wien-Tourismus/Christian-StemperThis year, BIO-Europe, Europe’s leading partnering event for the entire biotech ecosystem, will take place in Vienna. From 3 to 5 November, the industry’s most important decision-makers will meet here to negotiate partnerships, contracts and financing, and to learn about the latest developments and trends. With over 5,700 participants from 60 countries, 2025 is set to see a record number of delegates, sponsors, exhibitors and presenting companies.
Rezon BioThe global biologics industry is entering a new phase of maturity. As costs tighten and timelines accelerate, CDMOs must deliver uncompromised quality while driving efficiency. Rezon Bio, an EU-based biologics CDMO with state-of-the-art facilities and a client-centric approach, was established to meet biotech and pharmaceutical client needs with agility, pragmatism, and trust.
Watch this expert-led session to explore the latest trends and insights in gene therapy, including how to model immunosuppressive regimens, key study-design considerations, and the importance of age categories in nonhuman primate research.
Download the guide to explore how forward-thinking organisations are leveraging digital transformation in manufacturing to overcome regulatory challenges, enhance compliance, and gain operational efficiencies across multiple European sites and jurisdictions.
Customized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
In biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Sino Biological has addressed this urgent need with the launch of ProPure™, an advanced line of endotoxin-free recombinant proteins.
CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid tumors. On June 1, 2025, The Lancet published positive results from the world’s first randomized controlled trial of CLDN18.2 specific CAR-T in gastric cancer, led by Professor Lin Shen’s team at Peking University.
Sino BiologicalStick, Tag, Destroy: The Science of PROTACs and MGDs – For a long time, traditional drug research focused on inhibitors that block the active sites of disease-related proteins. However, around 80% of these proteins remain “undruggable” because they lack clear binding sites.
POWTECH TECHNOPHARM (Nuremberg, 23-25 September 2025) is the international trade fair for process engineering experts and a tailor-made technology platform for the pharmaceutical and life science industries.